Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer

Axitinib, small molecule tyrosine kinase inhibitor, demonstrates anti-cancer activity for various solid tumors. We investigated anti-cancer effect of axitinib in epithelial ovarian cancer (EOC). We treated EOC cells (A2780, HeyA8, RMG1, and HeyA8-MDR) with axitinib to evaluate its effects on cell vi...

Descripción completa

Detalles Bibliográficos
Autores principales: Paik, E Sun, Kim, Tae-Hyun, Cho, Young Jae, Ryu, Jiyoon, Choi, Jung-Joo, Lee, Yoo-Young, Kim, Tae-Joong, Choi, Chel-Hun, Kim, Woo Young, Sa, Jason K., Lee, Jin-Ku, Kim, Byoung-Gie, Bae, Duk-Soo, Han, Hee Dong, Ahn, Hyung Jun, Lee, Jeong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078214/
https://www.ncbi.nlm.nih.gov/pubmed/32184452
http://dx.doi.org/10.1038/s41598-020-61871-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078214/
https://www.ncbi.nlm.nih.gov/pubmed/32184452
http://dx.doi.org/10.1038/s41598-020-61871-w

Ejemplares similares